Skip to main content
Quest Diagnostics

Tick-Borne Disease Molecular Testing Positivity and Coinfection Incidence in the Northeastern United States: 2021-2023

AACC/ADLM 2024

The Association for Diagnostics & Laboratory Medicine (formerly ACC)

Chicago, IL, July 28-Aug 1, 2024

Poster presentation: Tick-Borne Disease Molecular Testing Positivity and Coinfection Incidence in the Northeastern United States: 2021-2023

Authors: Pratt G, Matsushita F, Bi C, Rao LV

Specialty: Infectious disease

Related content

Publication
A Comparison of Lyme Serological Testing Platforms with a Panel of Clinically Characterized Samples from Various Stages of Lyme Disease
On-Demand Webinar
Tick-borne Illness A Panel Discussion About Emerging Diagnostics Insights
Test FAQ
Lyme Disease Testing
Publication
Utility of Whole Blood Real-Time PCR Testing for the Diagnosis of Early Lyme Disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.